La vendita allo scoperto per Novartis dà agli investitori un'idea del grado in cui gli investitori stanno scommettendo sul declino delle azioni di Novartis. I dati relativi alle vendite allo scoperto vengono aggiornati ogni due settimane.

Novartis (NYSE:NVS) Azioni, Report sulle vendite allo scoperto

Novartis

Novartis develops and manufactures innovative drugs. The firm's key areas of drug development include oncology, rare diseases, neuroscience, immunology, respiratory, cardio-metabolic, and established medicines. The company sells its products globally, with the United States comprising close to one third of total revenue.

Novartis AG

NEVADA SUNRISE METALS CRP by NEVADA SUNRISE METALS CORP.

Nevada Sunrise Metals Corp

NOVUS HLDGS LTD SHS by NOVUS HLDGS LTD SHS

Novus Holdings Ltd

Envista Holdings Corporation Common Stock

Envista Holdings Corp

On Thursday, Novartis AG (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/NVS#NYSE">NVS</a>) raised its mid-term sales guidance, increasing its compound annual growth rate (CAGR) target to 6% from 5% for 2023-2028.
The upgrade reflects performance from current growth drivers and anticipated launches, many of which are expected to retain U.S. exclusivity into the 2030s.
The <a target="_blank" href="https://www.novartis.com/news/media-releases/novartis-upgrades-mid-term-guidance-and-highlights-deep-pipeline-core-therapeutic-areas-drive-long-term-growth" rel="noreferrer noopener">updated</a> forecast, announced ahead of the company's Meet Novartis Management event in London, underscores its confidence in sustained momentum.
Novartis has outlined its projections for 2024-2029, maintaining a 5% CAGR target with 2024 as the base year.
The company remains on track to achieve a core operating income margin of over 40% by 2027, supported by continued sales growth and productivity enhancements.
Also Read: <a target="_blank" href="https://www.benzinga.com/analyst-ratings/analyst-color/24/10/41634528/positive-outlook-for-novartis-as-company-capitalizes-on-growing-treatment-opportuni" rel="noreferrer noopener">Positive Outlook For Novartis As Company Capitalizes On Growing Treatment Opportunities, Analyst Highlights</a>
The company said the business is gaining strong momentum, with eight marketed brands expected to generate $3 billion to $8 billion at peak sales.
CEO Vas Narasimhan noted increased peak sales estimates for flagship drugs, including Cosentyx, Kisqali, Kesimpta, Pluvicto, and Leqvio, alongside 15 pivotal submission-enabling readouts in the pipeline.
He highlighted the company's long-term strategy, identifying more than 30 promising pipeline assets poised to rejuvenate its portfolio and sustain mid-single-digit growth beyond 2029.
Over the past two years, Novartis has executed more than 30 deals targeting exploratory and preclinical stages. Recent acquisitions, such as Kate Therapeutics and a collaboration with Ratio Therapeutics, bolster its radioligand and gene therapy pipelines, expanding opportunities in neuromuscular and radiotherapeutic advancements.
In October, Novartis reported third-quarter sales of $12.823 billion, up 9% (+10% on constant currency), beating the consensus of $12.76 billion. Volume contributed 12 percentage <a target="_blank" href="https://www.benzinga.com/general/biotech/24/10/41598312/novartis-q3-earnings-beats-expectations-on-strong-sales-from-key-drugs-lifts-2024-outlook" rel="noreferrer noopener">points to growth</a>.
The company said, "All key growth drivers contributed to the momentum. We achieved important indications expansions for&nbsp;Kisqali&nbsp;in early breast cancer and&nbsp;Fabhalta&nbsp;in IgA nephropathy&#8230;"
Novartis has <a target="_blank" href="https://www.novartis.com/stories/addressing-unmet-needs-inherited-neuromuscular-diseases" rel="noreferrer noopener">acquired</a> Kate Therapeutics to enhance and strengthen its portfolio of gene therapies.
Kate Therapeutics is a San Diego-based, preclinical-stage biotechnology company focused on developing adeno-associated virus (AAV)-based gene therapies to treat genetically defined neuromuscular diseases.&nbsp;
The transaction value is up to $1.1 billion, comprising an upfront payment and potential additional milestone payments.
Kate Therapeutics' primary programs include preclinical candidates for Duchenne muscular dystrophy, facioscapulohumeral dystrophy, and myotonic dystrophy type 1.
Price Action: NVS stock is up 0.24% at $103.34 at the last check on Thursday.
Read Next:
<ul>
<li><a href="https://www.benzinga.com/general/health-care/24/11/42098042/carlyle-sells-quidelortho-shares-analyst-sees-overhang-lifted" target="_blank" rel="noreferrer noopener">Carlyle Sells QuidelOrtho Shares, Analyst Sees Overhang Lifted</a></li>
</ul>
Photo by Taljat David via Shutterstock

Biotech

Large Cap

News

Guidance

Eurozone

Health Care

General

Novartis Elevates Midterm Sales Forecast, CEO Highlights Robust Pipeline

<ul>
<li>Rolling forward its mid-term guidance with strong 2024 performance as the base year, Novartis now expects to grow sales at +5% CAGR 2024-2029.&nbsp;</li>
<li>The company remains on track to deliver core operating income margin1 of 40%+ by 2027, benefiting from continued strong sales growth and productivity improvements.</li>
<li>"Novartis has completed its transformation into a pure-play innovative medicines company, with deep expertise and capabilities across our core therapeutic areas and technology platforms. Our focus has allowed us to sharpen our commercial execution and increase our peak sales estimates for Cosentyx, Kisqali, Kesimpta, Pluvicto and Leqvio, and we have more than 15 submission-enabling readouts in the coming years to further bolster our growth profile," said Vas Narasimhan, CEO of Novartis. "Longer term, we've identified more than 30 assets in the pipeline with significant potential to rejuvenate our portfolio and support mid-single-digit growth post 2029. Taken together, we remain confident in our focused strategy and ability to deliver sustainable value creation for shareholders."</li>
</ul>

Novartis Upgrades Its Mid-term Guidance. Previous Guidance For +5% Sales CAGR 2023-2028 Was Upgraded To +6%, Driven By Strong Momentum Of In-market Growth Drivers And Upcoming Launches, Most Of Which Have Expected US Exclusivity In 2030's Or Beyond

Collaboration will combine Vyriad's lentiviral vector platform and Novartis expertise and leadership in cell therapy innovation
ROCHESTER, Minn., Nov. 20, 2024 /PRNewswire/ -- Vyriad, Inc., a clinical-stage biotechnology company developing the next generation of targeted genetic therapies, today announced a strategic collaboration with Novartis to discover and develop in vivo chimeric antigen receptor (CAR) T-cell therapies.
The collaboration will leverage Vyriad's active targeting lentiviral vector platform and Novartis expertise and leadership in cell therapy innovation. Novartis and Vyriad will focus on the identification and development of in vivo CAR-T cell therapy candidates to be clinically advanced by Novartis. Vyriad will receive an upfront payment, milestone payments, and tiered royalties on each program.

Vyriad Announces Strategic Collaboration With Novartis To Develop In Vivo CAR-T Cell Therapies, Will Combine Vyriad's Lentiviral Vector Platform And Novartis Expertise And Leadership In Cell Therapy Innovation

Erste Group analyst Hans Engel downgrades Novartis (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/NVS#NYSE">NVS</a>) from Buy to Hold.

Downgrades

Analyst Ratings

Erste Group Downgrades Novartis to Hold

<a href="https://www.cdc.gov/bird-flu/spotlights/h5n1-response-11152024.html" title="https://www.cdc.gov/bird-flu/spotlights/h5n1-response-11152024.html">https://www.cdc.gov/bird-flu/spotlights/h5n1-response-11152024.html</a>

NVAX

U.S. CDC Says Since April Confirmed Avian Influenza A(H5) Virus Infections In 52 People In US; Aware Of Human Case Of H5N1 Bird Flu Reported In Canada & Is In Communication With Public Health Agency Of Canada

Ratio to receive upfront, and potential milestones and tiered royalty payments
BOSTON, Nov. 18, 2024 /PRNewswire/ -- Ratio Therapeutics Inc. (Ratio), a pharmaceutical company employing innovative technologies to develop best-in-class radiopharmaceuticals for cancer treatment and monitoring, entered today into an exclusive worldwide license and collaboration agreement with Novartis Pharma AG, a subsidiary of Novartis AG (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/NVS#NYSE">NVS</a>). The collaboration leverages Ratio's radioligand therapy discovery and development expertise as well as its technology platforms for the development of a Somatostatin Receptor 2 (SSTR2) radiotherapeutic candidate for cancer. &nbsp;&nbsp;

Ratio Therapeutics Enters License And Collaboration Agreement With Novartis For SSTR2-Targeting Radiotherapeutic Candidate; Under The Terms Of The Agreement, Ratio Will Receive Combined Upfront And Potential Milestone Payments Up To $745M

<a href="https://unemon.com/ResearchEasy/202411_INCY/20241115_INCY_Takeover_POA.html" title="https://unemon.com/ResearchEasy/202411_INCY/20241115_INCY_Takeover_POA.html">https://unemon.com/ResearchEasy/202411_INCY/20241115_INCY_Takeover_POA.html</a>

Rumors

Trading Ideas

INCY

Watching Incyte; Traders Circulate Research Report From Unemon Suggesting Novartis Emerges As The Ideal Acquirer, Says "Would Not Be Surprised To See A $105-$110 Deal In The Coming Weeks"

Schrodinger, Inc. (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/SDGR#NASDAQ">SDGR</a>) shares are trading higher on Tuesday. The company disclosed a research collaboration and license agreement with Novartis AG (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/NVS#NYSE">NVS</a>) to <a target="_blank" href="https://www.benzinga.com/pressreleases/24/11/b41896013/schr-dinger-announces-multi-target-collaboration-and-expanded-software-licensing-agreement-with-no" rel="noreferrer noopener">advance multiple development candidates</a>.
The companies also announced an extended&nbsp;three-year agreement that grants Novartis broad access to Schrödinger&#8217;s predictive modeling and informatics platform, enabling large-scale integration across research sites.
Karen Akinsanya, president of R&amp;D, therapeutics at Schrödinger, said, &#8220;We are delighted to work with Novartis and leverage their strong expertise to jointly advance several of Schrödinger&#8217;s existing non-oncology discovery programs as well as collaborate on additional programs.&#8221;
Schrödinger will support full platform integration to enhance computational drug discovery for Novartis. As per the terms, Novartis will pay Schrödinger $150 million upfront, with potential for up to $892 million in research, development, and regulatory milestones, plus up to $1.38 billion in commercial milestones. Schrödinger will also earn tiered royalties.
Ramy Farid, chief executive officer of Schrödinger stated, &#8220;We are very pleased to enable the further integration of our platform across Novartis&#8217; research teams to realize our shared vision for modernizing drug discovery through a computational &#8220;predict first&#8221; approach.&#8221;
Additionally, in a separate release, the company reported third-quarter revenue of $35.3&nbsp;million, missing the <a target="_blank" href="https://www.benzinga.com/pressreleases/24/11/b41896184/schr-dinger-reports-third-quarter-2024-financial-results" rel="noreferrer noopener">consensus of $40.57 million</a>.
Software revenue rose 10% to $31.9 million, led by increased hosted license contributions. Adjusted loss per share of 87 cents missed <a href="https://www.benzinga.com/earnings" target="_blank" rel="noreferrer noopener">the street view for a loss of 60 cents.</a>
As of September 30, 2024, Schrödinger had cash, cash equivalents, restricted cash and marketable securities stood at $398.4 million.
Outlook: Schrödinger now anticipates 2024 software revenue growth of 8% &#8211; 13%, compared to its previous 6% &#8211; 13% range, while lowering its drug discovery revenue guidance to $20 million &#8211; $30 million from the prior <a target="_blank" href="https://www.benzinga.com/calendars/guidance" rel="noreferrer noopener">guidance of $30 million &#8211; $35 million</a>.
Geoff Porges, MBBS, chief financial officer of Schrödinger said, &#8220;This quarter we added $48 million to our cash balance as a result of Lilly&#8217;s acquisition of Morphic and expect to add even more capital from the payments associated with the collaboration announced today.&#8221;
Investors can gain exposure to the stock via&nbsp;ARK Genomic Revolution ETF (BATS:<a class="ticker" href="https://www.benzinga.com/stock/ARKG#BATS">ARKG</a>).
Price Action: SDGR shares are up 14.6% at $22.40 at the last check Tuesday.
Image sourced from Shutterstock
Read Next:
<ul>
<li><a href="https://www.benzinga.com//node/41904976" target="_blank" rel="noreferrer noopener">Novavax Lowers 2024 Forecast Despite Q3 Revenue Beat, Stock Falls</a></li>
</ul>

Earnings

Equities

Contracts

Small Cap

Movers

ARKG

SDGR

Schrödinger Scores Big Despite Q3 Miss As Novartis Collaboration Promises Billions In Milestones: Details

<ul>
<li>The companies also announced an expanded three-year software agreement that substantially increases Novartis's access to Schrödinger's computational predictive modeling technology and enterprise informatics platform.&nbsp;</li>
<li>s part of the multi-year, multi-target research collaboration and license agreement, Schrödinger and Novartis will combine their existing research efforts to identify and advance therapeutics for undisclosed targets in Novartis's core therapeutic areas. The agreement is intended to advance multiple development candidates for development and commercialization by Novartis. Schrödinger and Novartis will share responsibility for the discovery of development candidates under the collaboration. Novartis will be responsible for clinical development, manufacturing and global commercialization.</li>
<li>Under the terms of the agreement, Novartis will pay Schrödinger $150 million upfront, and Schrödinger will also be eligible to receive up to $892 million in research, development and regulatory milestone payments. Additionally, Schrödinger is eligible for up to $1.38 billion in commercial milestones and tiered mid single-digit to low double-digit royalties on net sales of each product commercialized by Novartis.</li>
</ul>

Schrödinger Announced Research Collaboration And License Agreement With Novartis To Advance Multiple Development Candidates Into Novartis's Portfolio For Further Development, Schrödinger To Receive $150M Upfront And Eligible To Receive Up To Approximately $2.3B In Milestone Payments Plus Royalties

On Tuesday, Novartis AG (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/NVS#NYSE">NVS</a>) reported third-quarter sales of $12.823 billion, up 9% (+10% on constant currency), beating the <a target="_blank" href="https://www.benzinga.com/general/biotech/24/10/41598312/novartis-q3-earnings-beats-expectations-on-strong-sales-from-key-drugs-lifts-2024-outlook" rel="noreferrer noopener">consensus of $12.76 billion</a>.
Guidance: Novartis also raised its 2024 full-year guidance again this year.
In a statement, Novartis said it expects full-year core operating income to grow by a &#8220;high teens&#8221; percentage, compared with previous guidance of a &#8220;mid-to-high teens&#8221; percentage.
Novartis forecasts full-year sales growth in the low double digits, having previously guided for high-single to low-double-digit growth.
Pelabresib filing was further delayed, triggering a $800 million impairment charge related to the $2.9 billion <a target="_blank" href="https://www.benzinga.com/general/biotech/24/04/38497134/morphosys-says-novartis-deal-progressing-steadily-despite-safety-concerns-over-bone-marrow-cancer" rel="noreferrer noopener">acquisition of MorphoSys</a>.
Earlier this year, MorphoSys faced&nbsp;a burgeoning safety concern surrounding&nbsp;pelabresib.
Goldman Sachs notes that MorphoSys-related impairment charge is somewhat underwhelming, raising doubts about the company&#8217;s M&amp;A strategy.
Truist notes that Novartis is concentrating on preparing the market for the PSMAFore label, which is expected to triple its addressable market.
They also pointed out that growth opportunities in China and Japan, and metastatic hormone-sensitive prostate cancer (mHSPC) and oligometastatic disease, could push Pluvicto&#8217;s sales well above the projected $2 billion peak.
The company is committed to maximizing the potential of Pluvicto and its radioligand therapy (RLT) portfolio.
For other radiopharmaceutical companies targeting PSMA, entering this market may become more challenging.
A crucial question remains regarding the standards that must be met to compete with more effective radioligand products. This context relates to companies such as Eli Lilly And Co (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/LLY#NYSE">LLY</a>) and Bristol Myers Squibb &amp; Co (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/BMY#NYSE">BMY</a>), which have RLT products in their pipelines, as well as smaller companies, including Y-mAbs Therapeutics Inc (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/YMAB#NASDAQ">YMAB</a>) and Perspective Therapeutics Inc (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/CATX#NASDAQ">CATX</a>).
Novartis highlighted continued strong growth and momentum and sees room to grow the market size for B-cell inhibition in multiple sclerosis, relating Biogen Inc (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/BIIB#NASDAQ">BIIB</a>).
Truist highlights Novartis&#8217; strong balance sheet, which enables further bolt-on deals and share buybacks. Recent transactions primarily involve deals in the sub-$1 billion range, along with a few larger bolt-on acquisitions.
A Truist analyst indicated that they will be monitoring how the adoption of Leqvio may affect Amgen Inc&#8216;s (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/AMGN#NASDAQ">AMGN</a>) Repatha and Regeneron Pharmaceuticals Inc&#8216;s (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/REGN#NASDAQ">REGN</a>) Praluent. Meanwhile, Novartis has reported that the launch is advancing smoothly, and Leqvio continues to grow, outpacing the overall market as per the management.
Novartis&#8217; Cosentyx witnessed strong uptake and continued brand growth driven by hidradenitis suppurativa expansion, and the market opportunity can accommodate several players, Abbvie Inc (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/ABBV#NASDAQ">ABBV</a>), Incyte Corporation (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/INCY#NASDAQ">INCY</a>), and Kymera Therapeutics, Inc. (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/KYMR#NASDAQ">KYMR</a>).
Price Action: NVS stock is down 0.48% at $110.00 at last check Wednesday.
Photo by Taljat David via Shutterstock
Read Next:
<ul>
<li><a href="https://www.benzinga.com/news/earnings/24/10/41629995/orthopedic-implant-maker-zimmer-biomet-reports-better-than-expected-q3-earnings-updates-annual-fore" target="_blank" rel="noreferrer noopener">Orthopedic Implant Maker Zimmer Biomet Reports Better-Than-Expected Q3 Earnings, Updates Annual Forecasts</a></li>
</ul>

Analyst Color

ABBV

AMGN

BIIB

CATX

KYMR

REGN

YMAB

Positive Outlook For Novartis As Company Capitalizes On Growing Treatment Opportunities, Analyst Highlights

Last week, Lyell Immunopharma Inc.&nbsp;(NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/LYEL#NASDAQ">LYEL</a>) agreed to acquire ImmPACT Bio USA Inc., a privately owned clinical-<a target="_blank" href="https://www.benzinga.com/pressreleases/24/10/g41529414/lyell-immunopharma-to-acquire-immpact-bio-and-prioritizes-its-pipeline-to-focus-on-next-generation" rel="noreferrer noopener">stage biotechnology company</a>.
Lyell has prioritized its pipeline to focus resources on its most differentiated CAR T-cell clinical programs, including IMPT-314 following the close of the acquisition and LYL119.
Also Read: <a target="_blank" href="https://www.benzinga.com/general/biotech/24/06/39510265/lyell-immunopharma-shares-plunge-on-one-patient-death-in-car-t-cell-therapy-cancer-trial" rel="noreferrer noopener">Lyell Immunopharma Shares Plunge On One Patient Death In CAR-T Cell Therapy Cancer Trial</a>
Lyell announced the discontinuation of the development of LYL797 to focus on the Phase 1 clinical trial of LYL119, which is expected to initiate enrollment of patients with platinum-resistant ovarian cancer or relapsed/refractory endometrial cancer this year or early next year.
The LYL845 tumor-infiltrating lymphocyte (TIL) program is also being discontinued, as the clinical data in patients with advanced melanoma did not meet pre-determined criteria for continued development.
Its next-generation TIL and rejuvenation programs that are in preclinical development will also be discontinued.
Lyell expects its cash balance to fund operations into 2027.
Deal terms include upfront consideration of $30 million in cash and 37.5 million Lyell shares.
ImmPACT shareholders will also be eligible for contingent consideration consisting of 12.5 million Lyell shares and a low single-digit royalty on future net sales.
BofA Securities has downgraded Lyell from Buy to Underperform, with a price target of $1, <a target="_blank" href="https://www.benzinga.com/quote/LYEL/analyst-ratings" rel="noreferrer noopener">down from $6</a>.
The analyst said, &#8220;While discontinuation of &#8216;797 isn&#8217;t a surprise, we think optimism is growing for next-gen &#8216;119&#8217;s improved therapeutic window.&#8221;
The acquisition of ImmPACT Bio for its IMPT-314 introduces complexities that could cloud the narrative. The analyst added that while the potential of &#8216;314 is visible, the program appears to lack clinical and commercial synergy, and with limited resources and rising competition, it risks becoming a distraction.
An analyst noted that with Lyell's focus on restarting its solid tumor program and expanding into hematology, it's challenging to maintain a positive outlook.
It remains uncertain if IMPT-314 can provide significant clinical improvements, and it will likely face tough competition from established players like Gilead Sciences Inc (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/GILD#NASDAQ">GILD</a>), Bristol Myers Squibb &amp; Co (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/BMY#NYSE">BMY</a>), and Novartis AG (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/NVS#NYSE">NVS</a>).
Price Action: LYEL stock is down 9.16% at $0.86 at last check Wednesday.
Read Next:
<ul>
<li><a href="https://www.benzinga.com/news/24/10/41631621/netflix-restructures-leadership-bids-farewell-to-two-key-executives" target="_blank" rel="noreferrer noopener">Netflix Restructures Leadership, Bids Farewell to Two Key Executives</a></li>
</ul>
Image created using artificial intelligence via Midjourney.

Penny Stocks

GILD

LYEL

Lyell Immunopharma Downgraded, Analyst Flags Concerns Over Acquisition Strategy

<a href="https://www.aphis.usda.gov/news/agency-announcements/federal-state-veterinary-agencies-share-update-hpai-detections-oregon" title="https://www.aphis.usda.gov/news/agency-announcements/federal-state-veterinary-agencies-share-update-hpai-detections-oregon">https://www.aphis.usda.gov/news/agency-announcements/federal-state-veterinary-agencies-share-update-hpai-detections-oregon</a>

USDA Says H5N1 Bird Flu Detected In Swine For The First Time In U.S. In Oregon Backyard Farm; There Is No Concern About Safety Of The Nation's Pork Supply As A Result Of This Finding On HPAI Detections In Oregon Backyard Farm

USDA To Begin Bulk Milk Testing For Bird Flu Nationwide Following Pressure From Industry And Veterinary Groups; New Effort Aims To Curb Rapid Spread Among Dairy Herds

BMO Capital analyst Etzer Darout maintains Novartis (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/NVS#NYSE">NVS</a>) with a Market Perform and raises the price target from $118 to $120.

Price Target

BMO Capital Maintains Market Perform on Novartis, Raises Price Target to $120

<a href="https://www.fda.gov/drugs/resources-information-approved-drugs/fda-approves-asciminib-philadelphia-chromosome-positive-chronic-myeloid-leukemia" title="https://www.fda.gov/drugs/resources-information-approved-drugs/fda-approves-asciminib-philadelphia-chromosome-positive-chronic-myeloid-leukemia">https://www.fda.gov/drugs/resources-information-approved-drugs/fda-approves-asciminib-philadelphia-chromosome-positive-chronic-myeloid-leukemia</a>

FDA Grants Accelerated Approval To Novartis's Asciminib For Philadelphia Chromosome-Positive Chronic Myeloid Leukemia; Clinical Trial Shows 25% Major Molecular Response Rate At 24 Weeks Compared To 13% For Bosutinib

<a href="https://www.cdc.gov/bird-flu/spotlights/bird-flu-response-10-29-24.html#:~:text=Since%20April%202024%2C%20CDC%2C%20working,infected%20dairy%20cows12" title="https://www.cdc.gov/bird-flu/spotlights/bird-flu-response-10-29-24.html#:~:text=Since%20April%202024%2C%20CDC%2C%20working,infected%20dairy%20cows12">https://www.cdc.gov/bird-flu/spotlights/bird-flu-response-10-29-24.html#:~:text=Since%20April%202024%2C%20CDC%2C%20working,infected%20dairy%20cows12</a>.

Macro Notification

US CDC Reports 36 H5 Bird Flu Cases In U.S. Since April; Six Cases In Washington Poultry Workers Confirmed Last Week; No Person-To-Person Spread Detected; Public Risk Remains Low But Higher For Those Exposed To Infected Animals; 15 Cases Linked To Infected Poultry And 20 To Sick Dairy Cows

On Tuesday, Novartis AG (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/NVS#NYSE">NVS</a>) reported third-quarter sales of $12.823 billion, up 9% (+10% on constant currency), beating the consensus of $12.76 billion. Volume contributed 12 percentage points to growth.
The Swiss pharma giant <a target="_blank" href="https://www.novartis.com/news/media-releases/novartis-continues-strong-momentum-q3-10-sales-growth-20-core-operating-income-growth-and-important-innovation-milestones-raises-fy-2024-guidance" rel="noreferrer noopener">reported</a> adjusted EPS of $2.06, up from $1.74 a year ago and beating the consensus of $1.96
Core operating profit for the third quarter grew to $5.15 billion from $4.41 billion the year prior.
Also Read: <a target="_blank" href="https://www.benzinga.com/general/biotech/24/10/41407901/european-medicines-agencys-panel-supports-approval-of-novartis-kisqali-in-patients-with-early-bre" rel="noreferrer noopener">European Medicines Agency&#8217;s Panel Supports Approval Of Novartis&#8217; Kisqali In Patients With Early-Breast Cancer</a>
Novartis generated $6 billion in free cash flow for the third quarter, up 18% year-over-year.
&#8220;All key growth drivers contributed to the momentum. We achieved important indications expansions for&nbsp;Kisqali&nbsp;in early breast cancer and&nbsp;Fabhalta&nbsp;in IgA nephropathy, and we completed our PSMAfore filing for&nbsp;Pluvicto&nbsp;in the US. With the momentum in our business and pipeline, we were able to once again upgrade our full-year guidance and remain highly confident in our mid-term outlook,&#8221; said CEO Vas Narasimhan.
Quarterly Cosentyx sales gained 27% to $1.69 billion, driven by recent launches (including the HS indication and the IV formulation in the US) and volume growth in core indications.
Heart failure drug Entresto sales increased 26% to $1.87 billion, a demand-led growth. The drug has increased penetration in the U.S. and Europe following guideline-directed medical therapy for heart failure and in China with increased penetration in hypertension.
Multiple sclerosis drug Kesimpta sales reached $838 million, up +28%, reflecting increased demand for a high-efficacy product with convenient self-administered dosing.
Guidance: Novartis also raised its 2024 full-year guidance again this year.
In a statement, Novartis said it expects full-year core operating income to grow by a &#8220;high teens&#8221; percentage, compared with previous guidance of a &#8220;mid-to-high teens&#8221; percentage.
Novartis forecasts full-year sales growth in the low double digits, having previously guided for high-single to low-double-digit growth.
Price Action: NVS stock is down 3.29% at $111.82 during the premarket session at the last check on Tuesday.
Read Next:
<ul>
<li><a href="https://www.benzinga.com/markets/equities/24/10/41583904/volkswagen-plans-closure-of-three-factories-job-cuts-loom-report" target="_blank" rel="noreferrer noopener">Volkswagen Plans Closure Of Three Factories, Job Cuts Loom: Report</a></li>
</ul>
Photo by Taljat David via Shutterstock

Novartis Q3 Earnings Beats Expectations On Strong Sales From Key Drugs, Lifts 2024 Outlook

WIIM

Novartis shares are trading lower. The company reported Q3 financial results

&bull; Full-year 2024 guidance raised
&nbsp;o Net sales expected to grow low double-digit (from high single to low double-digit)
o Core operating income expected to grow high teens (from mid to high teens)

Novartis 2024 Guidance Raised: Now Expects Net Sales To Grow Low Double-Digit (From High Single To Low Double-Digit) And Core Operating Income To Grow High Teens (From Mid To High Teens)

Novartis (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/NVS#NYSE">NVS</a>) reported quarterly earnings of $2.06 per share which beat the analyst consensus estimate of $1.96 by 5.1 percent. This is a 18.39 percent increase over earnings of $1.74 per share from the same period last year. The company reported quarterly sales of $12.823 billion which beat the analyst consensus estimate of $12.764 billion by 0.46 percent. This is a 8.85 percent increase over sales of $11.780 billion the same period last year.

Earnings Beats

Novartis Q3 2024 Adj. EPS $2.06 Beats $1.96 Estimate, Sales $12.823B Beat $12.764B Estimate

In a report released today, Richard Vosser from J.P. Morgan maintained a Hold rating on Novartis AG (NOVN – Research Report), with a price target o...

J.P. Morgan Sticks to Their Hold Rating for Novartis AG (NOVN)

In a report released today, Matthew Weston from UBS maintained a Buy rating on Novartis AG (NOVN – Research Report), with a price target of CHF111....

UBS Sticks to Their Buy Rating for Novartis AG (NOVN)

Barclays analyst Emily Field maintained a Sell rating on Novartis AG (NOVN – Research Report) today and set a price target of CHF85.00. According t...

Barclays Sticks to Its Sell Rating for Novartis AG (NOVN)

In a report released today, James Quigley from Goldman Sachs maintained a Hold rating on Novartis AG (NOVN – Research Report), with a price target ...

Goldman Sachs Sticks to Its Hold Rating for Novartis AG (NOVN)

Analyst Graham Parry from Bank of America Securities reiterated a Hold rating on Novartis AG (NOVN – Research Report) and keeping the price target ...

Cautious Optimism: Balancing Novartis AG's Growth Projections with Market Skepticism and Patent Risks

Novartis (NVS) announced an upgrade to its mid-term guidance, in advance of its Meet Novartis Management event for investors and analysts in London...

Novartis provides updates to mid-term guidance, now sees 6% sales CAGR 2023-2028

Novartis raises mid-term sales guidance

Novartis buys gene therapy developer Kate for up to $1.1B

MoonLake Immunotherapeutics: A Somewhat Complicated Story

Novartis announced an upgrade for its sales CAGR today but investors don't seem overly impressed by the company's news.

Novartis Guidance Upgrade Fails to Impress Shareholders

MLTX

NVSEF

Press Releases

How Critical Demand for Metastatic Breast Cancer Therapies is Producing a Multi-Billion Dollar Opportunity for Biotechs

Generate:Biomedicines Announces Multi-Target Collaboration with Novartis to Discover and Develop Protein Therapeutics with Generative AI

As Fentanyl Crisis Escalates, Abuse-Deterrent Formulations to Zero in on the Rising Epidemic of Opiate Abuse

Opinion

Beyond the Horizon: Innovative Drug Combinations Offer New Hope for Alzheimer's and More

Breast Cancer Awareness Month Sees Biotech Advancements and Worrying Trends for Young Women

Novartis receives positive CHMP opinion for Kisqali® to help reduce risk of recurrence in people with HR+/HER2- early breast cancer

OS Therapies Appoints Two Bio-Pharmaceutical Industry Veterans to the Board of Directors

Seaport Therapeutics Names Lauren White as Chief Financial Officer

PureTech Founded Entity Seaport Therapeutics Names Lauren White as Chief Financial Officer

Ratio Enters License and Collaboration Agreement with Novartis for SSTR2-targeting Radiotherapeutic Candidate

AMRX

ANVS

ATOS

CCCC

DRIO

GLMD

HOLX

IMGN

KZIA

NTRB

NTRBW

ONCY

OSTX

PRTC

TEVA

TSX:ONC

Axsome Therapeutics

AstraZeneca PLC - American Depositary Shares

AstraZeneca

Bristol-Myers Squibb Company Common Stock

Bristol-Myers Squibb

Corcept Therapeutics Incorporated - Common Stock

Corcept Therapeutics

Catalent

Elanco Animal Health Incorporated Common Stock

Elanco Animal Health

GSK plc American Depositary Shares (Each representing two Ordinary Shares)

HUTCHMED (China) Limited - American Depositary Shares

HUTCHMED (China)

Intra-Cellular Therapies Inc. - Common Stock

Intra-Cellular Therapies

Jazz Pharmaceuticals plc - Ordinary Shares

Jazz Pharmaceuticals

Johnson & Johnson

Eli Lilly

Merck & Co

Novo Nordisk

Organon

Prestige Consumer Healthcare Inc. Common Stock

Prestige Consumer

Pfizer

Dr. Reddy's Laboratories Ltd Common Stock

Dr Reddy's Laboratories

Royalty Pharma plc - Class A Ordinary Shares

Royalty Pharma

Sanofi

Takeda Pharmaceutical Company Limited American Depositary Shares (each representing 1/2 of a share of Common Stock)

Comments

Novartis

Vendite allo scoperto

Novartis (NYSE:NVS) Azioni, Report sulle vendite allo scoperto

Le persone guardano anche

Notizie

PARTNER/COLLABORATORE

BENZINGA NEL MONDO